Two weeks ago, Merck (MRKpleasantly surprised investors by releasing promising top-line findings of a key lung cancer study for its Keytruda medicine. But a new survey suggests that some doctors remain squeamish about using the drug as a first-line treatment for their patients.

Specifically, 56 percent of 32 oncologists who were surveyed found the results encouraging, but are waiting for the complete study data to be released before they may use Keytruda as a first-line treatment, according to Bernstein analyst Tim Anderson, who commissioned the survey.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Father diagnosed with stage 4 lung cancer. PDL1 markers greater than 90%. May 11, 2017. Keytruda 200mg every 3 weeks. Passed away October 2, 2017. Did not work.

  • I have been on Keytruda every 21 days sice March 2017…i had lung cancer in both lungs. I am staying on Keytruda until spring for precautions but my cancer is gone. My doctor said i am a walking miracle!! I believe in Keytruda!!!

  • Mother 82, stage 4. Last January was lucky enough to take part in trial. Fox Chase suggested Kytruda. This Jan. Tumor has shrunk 2.8 to 1.1. No side effects. Tell everyone I know about this promising treatment. Thank you Merck.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy